Nystop

Pruritus Vulvae, Trichomonas Vaginitis, Pruritus Ani + 13 more

Treatment

13 Active Studies for Nystop

What is Nystop

Nystatin

The Generic name of this drug

Treatment Summary

Nystatin is an antifungal medication used to treat fungal infections, especially those caused by Candida species. It is derived from a type of bacteria called Streptomyces noursei and is similar to another antifungal medication, amphotericin B. Nystatin is most effective when taken orally or applied topically and is not suitable for systemic use because of its potential toxicity. It is mainly used to treat fungal infections of the skin, mucous membranes, and gastrointestinal tract.

Nystatin

is the brand name

image of different drug pills on a surface

Nystop Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nystatin

Nystatin

1979

252

Effectiveness

How Nystop Affects Patients

Nystatin is a medicine used to treat fungal infections. It works by damaging the cell membranes of the fungi, making it unable to survive. Nystatin typically works well against _Candida albicans_ but it can become resistant in other species of _Candida_. Nystatin does not work against bacteria, protozoa, or viruses and is not strong enough to be used for systemic infections. Therefore, it can only be used topically, orally, and in the gastrointestinal tract.

How Nystop works in the body

Nystatin is a drug that helps fight off certain types of fungus. It works by forming a tiny pore in the membrane of the fungus cells. This change in the cell's permeability causes the contents of the cell to leak out, which disrupts the electrical processes necessary for the cell to work. Nystatin is selective in that it binds more strongly to the cholesterol found in fungal cells than to the cholesterol found in human cells.

When to interrupt dosage

The measure of Nystop is contingent upon the identified condition, such as cutaneous candidiasis, Skin candida and corticosteroid-responsive dermatoses. The portion of dosage fluctuates, depending on the technique of delivery (e.g. Insert or Insert - Vaginal) featured in the table below.

Condition

Dosage

Administration

Skin candida

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Anal candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Skin Diseases

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Oral

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Low; Birthweight

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Pruritus Ani

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

cutaneous candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Urinary Tract Infection (UTI)

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candida albicans

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Pruritus Vulvae

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Trichomonas Vaginitis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Vulvovaginal

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Invasive

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Vulvovaginal

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Yeast Infection

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Warnings

Nystop has one contraindication, so it should not be ingested in cases of the afflictions listed in the table below.

Nystop Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nystatin may interact with Pulse Frequency

There are 20 known major drug interactions with Nystop.

Common Nystop Drug Interactions

Drug Name

Risk Level

Description

Revefenacin

Major

Nystatin may decrease the excretion rate of Revefenacin which could result in a higher serum level.

Ambrisentan

Minor

The excretion of Ambrisentan can be decreased when combined with Nystatin.

Asunaprevir

Minor

The excretion of Asunaprevir can be decreased when combined with Nystatin.

Atorvastatin

Minor

The excretion of Atorvastatin can be decreased when combined with Nystatin.

Atrasentan

Minor

The excretion of Atrasentan can be decreased when combined with Nystatin.

Nystop Toxicity & Overdose Risk

The lowest poisonous dose of nystatin for rats is 10g/kg. No major toxic effects have been reported from taking too much nystatin, however taking more than 5 million units a day has caused nausea and digestive problems.

image of a doctor in a lab doing drug, clinical research

Nystop Novel Uses: Which Conditions Have a Clinical Trial Featuring Nystop?

There are 39 active studies investigating the potential of Nystop to alleviate Urinary Tract Infection (UTI), Yeast Infection and Anal Itching.

Condition

Clinical Trials

Trial Phases

Pruritus Ani

0 Actively Recruiting

Candida albicans

0 Actively Recruiting

Skin candida

0 Actively Recruiting

Anal candidiasis

0 Actively Recruiting

Candidiasis, Invasive

4 Actively Recruiting

Phase 3, Not Applicable

Trichomonas Vaginitis

2 Actively Recruiting

Phase 2, Phase 4

Candidiasis, Oral

0 Actively Recruiting

Yeast Infection

0 Actively Recruiting

Low; Birthweight

2 Actively Recruiting

Not Applicable

Skin Diseases

0 Actively Recruiting

cutaneous candidiasis

0 Actively Recruiting

Candidiasis

0 Actively Recruiting

Candidiasis, Vulvovaginal

2 Actively Recruiting

Not Applicable, Phase 3

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Pruritus Vulvae

0 Actively Recruiting

Candidiasis, Vulvovaginal

0 Actively Recruiting

Nystop Reviews: What are patients saying about Nystop?

5

Patient Review

6/22/2015

Nystop for Skin Infection due to a Candida Yeast

I was recommended this powder by my doctor to help with the sweating and smells coming from my underboob area. This is the only powder that has worked without making me itch, and it's helped clear up my skin while getting rid of the odor other products couldn't handle. It's been a lifesaver during summer months when I'm outside working a lot.

5

Patient Review

1/22/2018

Nystop for Skin Infection due to a Candida Yeast

Because I have diabetes, I'm unfortunately more susceptible to yeast infections. However, this product has worked great for me every time it's been needed. I keep a bottle on hand so that I can address the issue as soon as it comes up.

5

Patient Review

3/27/2012

Nystop for Skin Infection due to a Candida Yeast

This product is really effective against yeast infections, especially for people with diabetes. I haven't found anything that works as well or as completely.

5

Patient Review

4/5/2022

Nystop for Skin Infection due to a Candida Yeast

I have diabetes and skin fold yeast became a problem for me 6 years ago and stayed with me. I just used OTC products and didn’t involve my doctor, probably due to pembarrassment. Finally, it became too much. Nystop along with fluconazole has helped and I am looking at nearly clear patches of skin for the first time. I am halfway through treatment and love the relief. I plan to keep the Nystop on hand as it has been incredibly effective for me.

5

Patient Review

3/4/2008

Nystop for Skin Infection due to a Candida Yeast

Nystop was very effective in halting the spread of the infection on my skin.

4.7

Patient Review

7/23/2014

Nystop for Skin Infection due to a Candida Yeast

This treatment was effective on my feet and toes.

4.3

Patient Review

1/31/2011

Nystop for Skin Infection due to a Candida Yeast

Nystop is a great product. I tried it and it worked for me.

3

Patient Review

5/3/2008

Nystop for Skin Infection due to a Candida Yeast

Question: Did anyone have skin peeling, after using this drug? I did and it was really annoying.

1.7

Patient Review

5/10/2013

Nystop for Diaper Rash

After using this treatment for only two days, I developed a severe rash that felt like chemical burns.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nystop

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Nystop over the counter?

"Nystatin is a prescription medication in the United States. It is available as a cream or powder."

Answered by AI

How long does it take for Nystop powder to work?

"It is important to continue taking or using nystatin for 2 days after your condition improves to help prevent it from recurring."

Answered by AI

What is Nystop powder used for?

"Nystatin is a topical powder used as an antibiotic to treat skin infections caused by yeast. It is available in generic form."

Answered by AI

Where do you apply Nystop powder?

"Use this medication on candidal lesions two to three times per day until the lesions have healed. If you have a fungal infection on your feet caused by Candida species, make sure to dust the powder on your feet and in all of your shoes."

Answered by AI

Clinical Trials for Nystop

Have you considered Nystop clinical trials?

We made a collection of clinical trials featuring Nystop, we think they might fit your search criteria.
Go to Trials
Image of University of Missouri in Columbia, United States.

Antibiotics for Cat Bite Injuries

18+
All Sexes
Columbia, MO

Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.

Phase 4
Recruiting

University of Missouri

Kevin M Klifto, DO, PharmD

Image of Children's Hospital of Philadelphia in Philadelphia, United States.

Antifungal Therapy Duration for Candidemia in Children

120 - 18
All Sexes
Philadelphia, PA

The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: * Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. * Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups. Participants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.

Recruiting
Has No Placebo

Children's Hospital of Philadelphia (+17 Sites)

Brian Fisher, DO

Image of Rush University Medical Center in Chicago, United States.

Menstrual Cups for Vaginal Infections

15 - 35
Female
Chicago, IL

HIV remains a global pandemic with 37 million infected. In western Kenya, 16% of women in the general population and 29% of the poorest women have HIV. The HIV and sexually transmitted infection (STI) epidemics overlap with broader reproductive health concerns. Menstrual hygiene management is a big problem in low- and middle-income countries and a lack of menstrual products negatively impacts women's work-life. This comes from cultural taboos, stigma, and discrimination, promoting secrecy around menstruation, high cost of menstrual products, use of traditional materials (e.g. rags, cotton wool, etc.) causing leakage and odor, and lack of water and safe hygiene facilities. Menstrual cups designed for use during sex may help women prevent Bacterial vaginosis (BV) and STIs through hygienic period practices, and may help them avoid bad practices in an attempt to maintain vaginal dryness. The goal of this interventional trial is to test the impact of menstrual cups on vaginal microbiome, BV, and STIs of poor women at high risk for STIs and HIV. We predict to see 25% less BV, our primary outcome, over one year. This trial aims to learn more about the safety of the intervention, and understand what is needed to fully implement the program.

Phase 2
Waitlist Available

Rush University Medical Center

Have you considered Nystop clinical trials?

We made a collection of clinical trials featuring Nystop, we think they might fit your search criteria.
Go to Trials
Image of University of North Carolina at Chapel Hill in Chapel Hill, United States.

Data Accountability + Doula Support for Maternal Health Disparities

12 - 99
Female
Chapel Hill, NC

This project-also known as "Accountability for Care through Undoing Racism \& Equity for Moms" or ACURE4Moms-aims to reduce Black-White maternal health disparities using multi-level interventions designed to decrease bias in prenatal care, improve care coordination, and increase social support. ACURE4Moms is a pragmatic 4-arm cluster randomized controlled trial conducted with 39 prenatal practices across North Carolina. Practices have been randomly assigned to receive either: Arm 1 (Standard Care): North Carolina Medicaid Care management for high-risk pregnancies; Arm 2 (Data Accountability and Transparency): North Carolina Medicaid Care Management + Practice-level Data Accountability interventions; Arm 3 (Community-Based Doula Support): North Carolina Medicaid Care Management + Community-Based Doula support intervention for high-risk patients during pregnancy and postpartum; or Arm 4 (Data Accountability and Transparency + Community-Based Doula Support): North Carolina Medicaid Care Management + Both Arms 2 and 3 interventions. During each practice's 2-year intervention period, the practice will initiate prenatal care for \~750-1,500 patients (up to 60,000 patients total), whose outcomes the investigators will follow and compare between arms until all these patients have reached 1-year post-delivery.

Recruiting
Has No Placebo

University of North Carolina at Chapel Hill

Jennifer H Tang, MD, MSCR

Image of Houston Methodist Hospital - Texas Medical Center in Houston, United States.

Fosmanogepix for Candida Blood Infection

18+
All Sexes
Houston, TX

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking patients who have a diagnosis of candidemia and/or invasive candidiasis. Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosmanogepix tablets. One-third of all patients will receive a standard of care regimen of caspofungin Intravenous (IV) infusion followed by optional fluconazole capsules. Fosmanogepix or caspofungin will first be given as an Intravenous (IV) infusion directly into a vein in the arm each day at the study clinic. Fosmanogepix tablets or fluconazole capsules will be taken orally by mouth daily either at the study clinic, or at home if patients are well enough to be discharged from the hospital. The treatment effect in patients receiving fosmanogepix to those receiving caspofungin/ fluconazole will be compared. The primary aim is to show that fosmanogepix is not inferior (not worse) to caspofungin/ fluconazole with a noninferiority margin of 15%. The duration of study treatment and number of study visits will vary depending on how long the patient will be treated for the infection. Treatment will continue for a maximum of 6 weeks depending on when the infection is cleared and whether other symptoms related to the infection have improved. There will also be a follow-up visit 6 weeks after the study treatment was stopped.

Phase 3
Recruiting

Houston Methodist Hospital - Texas Medical Center (+12 Sites)

Manuel Häckl, MD

Basilea Pharmaceutica